GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (NAS:MRUS) » Definitions » Shiller PE Ratio

Merus NV (Merus NV) Shiller PE Ratio : (As of May. 01, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Merus NV Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Merus NV Shiller PE Ratio Historical Data

The historical data trend for Merus NV's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Shiller PE Ratio Chart

Merus NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Merus NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Merus NV's Shiller PE Ratio

For the Biotechnology subindustry, Merus NV's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus NV's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Merus NV's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Merus NV's Shiller PE Ratio falls into.



Merus NV Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Merus NV's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Merus NV's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.09/126.4000*126.4000
=-1.090

Current CPI (Dec. 2023) = 126.4000.

Merus NV Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 0.000 98.360 0.000
201406 0.000 99.240 0.000
201409 -0.335 99.960 -0.424
201412 -0.414 99.050 -0.528
201503 -0.340 99.750 -0.431
201506 -0.405 100.230 -0.511
201509 -0.448 100.500 -0.563
201512 -0.437 99.730 -0.554
201603 -0.435 100.310 -0.548
201606 -0.445 100.260 -0.561
201609 -0.348 100.570 -0.437
201612 -2.009 100.710 -2.521
201703 -1.133 101.440 -1.412
201706 -1.155 101.370 -1.440
201709 -0.810 102.030 -1.003
201712 -0.876 101.970 -1.086
201803 -0.493 102.470 -0.608
201806 -0.231 103.100 -0.283
201809 -0.546 103.950 -0.664
201812 -0.023 103.970 -0.028
201903 -0.380 105.370 -0.456
201906 -0.520 105.840 -0.621
201909 -0.550 106.700 -0.652
201912 -0.820 106.800 -0.970
202003 -0.680 106.850 -0.804
202006 -0.540 107.510 -0.635
202009 -0.640 107.880 -0.750
202012 -1.060 107.850 -1.242
202103 -0.280 108.870 -0.325
202106 -0.710 109.670 -0.818
202109 -0.390 110.790 -0.445
202112 -0.340 114.010 -0.377
202203 -0.430 119.460 -0.455
202206 -0.130 119.050 -0.138
202209 -0.530 126.890 -0.528
202212 -1.810 124.940 -1.831
202303 -0.860 124.720 -0.872
202306 -0.660 125.830 -0.663
202309 -0.430 127.160 -0.427
202312 -1.090 126.400 -1.090

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Merus NV  (NAS:MRUS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Merus NV Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Merus NV's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus NV (Merus NV) Business Description

Traded in Other Exchanges
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Executives
Harry Shuman officer: Chief Accounting Officer C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Peter B. Silverman officer: EVP & General Counsel C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Sven Ante Lundberg director, officer: President, CEO & PFO C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Kruif John De officer: Chief Technology Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Paolo Pucci director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Len Kanavy director C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Maxine Gowen director
Anand Mehra director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Victor Sandor director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Mark T Iwicki director 84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Gregory D Perry director C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Geuijen Cecile A W officer: SVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584CM
Andrew Joe officer: SVP, CMO C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Mark Throsby officer: EVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM